Fabry disease: Dose matters

Journal of the American Society of Nephrology

Volumn 25, Issue 4, 2014, Pages 653-655

  Warnock, David G ^a   Mauer, Michael ^b  

^a and Clinical Center   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALBUMIN; ALPHA GALACTOSIDASE; CREATININE; GLOBOTRIAOSYLCERAMIDE; VASCULOTROPIN; ISOENZYME;

CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; EDITORIAL; ENDOTHELIUM CELL; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; MALE; MICROALBUMINURIA; PHARMACEUTICAL CARE; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; CHRONIC KIDNEY DISEASE; GENETIC RENAL DISEASE; NOTE;

CHRONIC KIDNEY DISEASE; GENETIC RENAL DISEASE; PROTEINURIA;

ALPHA-GALACTOSIDASE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE;

EID: 84901434009     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013121322     Document Type: Editorial

References (23)

1. Desnick RJ, Ioannou YA, Eng CM: Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic Bases of Inherited Disease, edited by Scriver C, Beaudet A, Sly W, Valle D, 8th Ed., New York, McGraw-Hill, 2001, pp 3733-3774
2. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB: Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122-138, 2002
3. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C; Fabry Registry: Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23: 1600-1607, 2008
4. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group: Safety and efficacy of recombinant human alphagalactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16, 2001
5. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285: 2743-2749, 2001
6. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO: Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21: 345-354, 2006
7. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ; Fabry Disease Clinical Trial Study Group: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146: 77-86, 2007
8. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557, 2007
9. Tahir H, Jackson LL, Warnock DG: Antiproteinuric therapy and Fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18: 2609-2617, 2007
10. Desnick RJ: Enzyme replacement therapy for Fabry disease: Lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 4: 1167-1176, 2004
11. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM: Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66: 1589-1595, 2004
12. Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M: Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583, 2007
13. Fervenza FC, Torra R, Warnock DG: Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics 2: 823-843, 2008
14. Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Gonzáles HG, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E: Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol 25: 837-849, 2014
15. Tsuboi K, Yamamoto H: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med 14: 779-786, 2012
16. Pisani A, Spinelli L, Visciano B, Capuano I, Sabbatini M, Riccio E, Messalli G, Imbriaco M: Effects of switching from agalsidase beta to agalsidase alfa in 10 patients with Anderson-Fabry disease. JIMD Rep 9: 41-48, 2013
17. Najafian B, Svarstad E, Bostad L, Gubler MC, Tøndel C, Whitley C, Mauer M: Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 79: 663-670, 2011
18. Kanai T, Yamagata T, Ito T, Odaka J, Saito T, Aoyagi J, Kobayashi M, Ohashi T, Ueda Y, Momoi MY: Foot process effacement with normal urinalysis in classic Fabry disease. JIMD Rep 1: 39-42, 2011
19. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ: Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24: 2102-2111, 2009
20. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Maródi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG: Prognostic indicators of renal disease progression in adults with Fabry disease: Natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5: 2220-2228, 2010
21. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Maródi L,Mignani R, Vujkovac B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C; Fabry Registry: Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27: 1042-1049, 2012
22. Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E: Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24: 137-148, 2013
23. Prabakaran T, Birn H, Bibby BM, Regeniter A, Sørensen SS, Feldt- Rasmussen U, Nielsen R, Christensen EI: Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease [published online ahead of print November 8, 2013]. Nephrol Dial Transplant doi:10.1093/ndt/gft452